GlassScriptPhysician profile
Kandi L Arwine
NPI 1801319181
$6,097.79
in general payments reported to CMS, 2019-2025
62 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $1,413 · 2023: $1,319 · 2024: $1,413 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198 · Education: $65.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.40 |
| Education | $65.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $459.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $354.46 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $314.36 | 2021-2024 | Lunsumio, Polivy, Columvi |
| Genzyme Corporation | $283.35 | 2021-2024 | |
| Celgene Corporation | $269.85 | 2022-2024 | Pomalyst, Reblozyl |
| Merck Sharp & Dohme LLC | $269.03 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $228.90 | 2022-2025 | Rybrevant, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $210.73 | 2021-2024 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals LP | $208.73 | 2021-2025 | Enhertu |
| Lilly USA, LLC | $205.63 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $197.76 | 2022-2025 | Libtayo |
| Gilead Sciences, INC. | $197.11 | 2021-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $161.59 | 2022-2025 | Fotivda |
| Amgen INC. | $161.52 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Abbvie INC. | $147.53 | 2024-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $146.86 | 2023-2025 | Orserdu |
| Spectrum Pharmaceuticals INC. | $144.38 | 2023-2025 | Rolvedon |
| Daiichi Sankyo INC. | $137.32 | 2022-2025 | Enhertu, Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $119.42 | 2023-2025 | Iclusig, Ninlaro, Fruzaqla |
| Pharmacosmos Therapeutics INC. | $114.23 | 2022-2024 | Cosela |
| Sobi, INC | $111.16 | 2024-2025 | |
| Incyte Corporation | $109.01 | 2022-2025 | Monjuvi, Pemazyre, Jakafi |
| Pfizer INC. | $105.61 | 2024-2025 | |
| Springworks Therapeutics, INC. | $101.16 | 2024-2025 | Ogsiveo |
| Tersera Therapeutics LLC | $94.89 | 2022-2025 | Zoladex |
| Novocure INC. | $91.56 | 2023-2024 | Optune, Optune Lua (Novottf-200t) |
| Rigel Pharmaceuticals, INC. | $81.20 | 2022-2024 | Tavalisse, Rezlidhia |
| Seagen INC. | $75.16 | 2021-2023 | Tukysa |
| Jazz Pharmaceuticals INC. | $71.52 | 2024-2025 | |
| Kite Pharma, INC. | $60.30 | 2022-2025 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $59.46 | 2022-2023 | Imbruvica |
| Beigene USA, INC. | $58.77 | 2021-2022 | |
| Organon LLC | $54.53 | 2022-2023 | Ontruzant |
| Apellis Pharmaceuticals, INC. | $48.61 | 2023-2024 | Empaveli |
| Kyowa Kirin, INC. | $38.76 | 2023 | Poteligeo |
| Astellas Pharma US INC | $37.96 | 2025 | Vyloy |
| Ipsen Biopharmaceuticals, INC | $35.77 | 2021-2025 | Onivyde |
| Genmab U.S., INC. | $33.31 | 2024-2025 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $33.27 | 2022 | |
| Sumitomo Pharma America, INC. | $32.44 | 2023-2024 | Orgovyx |
| Puma Biotechnology, INC. | $31.53 | 2021-2023 | Nerlynx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.27 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $27.83 | 2025 | Enjaymo |
| Invivyd INC | $25.83 | 2025 | Pemgarda |
| Iovance Biotherapeutics, INC. | $23.09 | 2024 | Amtagvi |
| Adaptive Biotechnologies Corporation | $22.48 | 2023 | Clonoseq |
| Cti Biopharma Corp. | $22.40 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Geron Corporation | $21.03 | 2025 | Rytelo |
| Epizyme, INC. | $19.17 | 2022 | |
| Emd Serono, INC. | $19.03 | 2023 | Bavencio |
| Alnylam Pharmaceuticals INC. | $18.26 | 2023 | Amvuttra |
| Taiho Oncology, INC. | $16.85 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.97 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.90 | 2021 | |
| Acceleron Pharma, INC. | $15.71 | 2021 | |
| Exelixis INC. | $14.69 | 2021 | |
| Immunocore Limited | $14.67 | 2024 | Kimmtrak |
| Eagle Pharmaceuticals, INC. | $14.47 | 2023 | |
| Deciphera Pharmaceuticals INC. | $13.88 | 2025 | Qinlock |
| Blueprint Medicines Corporation | $13.55 | 2021 | |
| Myriad Genetic Laboratories, INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kandi Arwine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.